These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31392665)

  • 21. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
    Dubois RW; Westrich K
    Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine.
    Fragoulakis V; Mitropoulou C; van Schaik RH; Maniadakis N; Patrinos GP
    OMICS; 2016 May; 20(5):274-82. PubMed ID: 27096406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment.
    Incerti D; Thom H; Baio G; Jansen JP
    Value Health; 2019 May; 22(5):575-579. PubMed ID: 31104737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?
    Karnon J; Partington A
    Pharmacoeconomics; 2015 Dec; 33(12):1281-8. PubMed ID: 26100285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Overview of R in Health Decision Sciences.
    Jalal H; Pechlivanoglou P; Krijkamp E; Alarid-Escudero F; Enns E; Hunink MGM
    Med Decis Making; 2017 Oct; 37(7):735-746. PubMed ID: 28061043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.
    Brown J; Cook K; Adamski K; Lau J; Bargo D; Breen S; Chawla A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):153-164. PubMed ID: 28335636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH; Kumar V
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NIH consensus development conference draft statement on vaginal birth after cesarean: new insights.
    Cunningham FG; Bangdiwala SI; Brown SS; Dean TM; Frederiksen M; Rowland Hogue CJ; King T; Spencer Lukacz E; McCullough LB; Nicholson W; Petit NF; Probstfield JL; Viguera AC; Wong CA; Zimmet SC
    NIH Consens State Sci Statements; 2010 Mar; 27(3):1-42. PubMed ID: 20228855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.
    Bosch-Barrera J; Quer N; Brunet J
    Clin Lung Cancer; 2011 Nov; 12(6):335-40. PubMed ID: 21816680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine.
    Padula WV; McQueen RB; Pronovost PJ
    Med Care; 2017 Nov; 55(11):915-917. PubMed ID: 29028755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lung cancer management in limited resource settings: guidelines for appropriate good care.
    Macbeth FR; Abratt RP; Cho KH; Stephens RJ; Jeremic B;
    Radiother Oncol; 2007 Feb; 82(2):123-31. PubMed ID: 17239979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.